Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles☆

Date, Abhijit A.; Joshi, Medha; Patravale, Vandana

doi:10.1016/j.addr.2007.04.009

Cited by 248 publications

(131 citation statements)

References 134 publications

Supporting

Mentioning

125

Contrasting

Unclassified

Order By: Relevance

“…These situations warrant the application of novel drug delivery approaches, which have shown success in the past in overcoming the pharmacokinetic mismatches such as controlled release, bioavailability, stability, etc. to other drug molecules, which are in use to treat similar parasitic infections in general and malaria in particular (Date et al, 2007;Santos-Magalhães & Mosqueira, 2010;Aditya et al, 2013b). Thus, the aim of this research is to fabricate injectable (intraperitoneal; i.p.)…”

Section: Introductionmentioning

confidence: 99%

Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity

2014

View full text Add to dashboard Cite

Context: Artemether and lumefantrine combination therapy is well-accepted for uncomplicated malaria treatment. However, the current available formulation has several pharmacokinetic mismatches such as drug degradation in gastrointestinal tract, erratic absorption, etc. Hence, need of the hour is the injectable formulation, which can overcome the pharmacokinetic mismatch associated with current available formulation in the market. Objective: To fabricate artemether and lumefantrine co-loaded injectable nanostructured lipid carriers (NLCs) formulation. Materials and methods: Artemether and lumefantrine co-loaded NLCs were fabricated using homogenization followed by ultra-sonication method. Fabricated NLCs were evalauated for their physicochemical characteristics, and suitability of the formulation for malaria treatment was evaluated using in vivo animal model (Plasmodium berghei-infected mice). Results, discussion and conclusion: Artemether and lumefantrine co-loaded NLCs had a hydrodynamic diameter of $145 nm with the surface charge of À66 mV. Due to the lipophilic nature of both antimalarial drugs, both single drugs-loaded and co-loaded NLCs have shown high encapsulation efficiency, which is 84% for artemether and 79% for lumefantrine. In vitro drug release study has shown a biphasic drug release pattern, which has shown 63% artemether release and 45% of lumefantrine release over a time period of 30 h. Plasmodium berghei-infected mice treated with artemether and lumefantrine co-loaded NLCs showed better antimalarial activity with respect to parasitemia progression and survivability period.

show abstract

Section: Introductionmentioning

confidence: 99%

Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity

2014

View full text Add to dashboard Cite

show abstract

“…and can be used to treat several types of parasitic infections [29][30][31][32][33]. Obviously it is very important to understand nature of biological and cellular membranes at target site, distribution and presence of drug receptors and enzymes responsible for drug metabolism.…”

Section: Introductionmentioning

confidence: 99%

Present status of nanoparticle research for treatment of Tuberculosis

2011

View full text Add to dashboard Cite

-Nanotechnology has offered enormous improvement in field of therapeutics by means of designing of drug delivery systems and opened the possibility of controlling infections at the molecular level. Nanocarriers can cross biological barriers and are able to target cellular reservoirs of Mycobacterium tuberculosis (M. tuberculosis). Nanoparticle-based systems have significant potential for treatment and prevention of tuberculosis (TB). A variety of nanocarriers have been widely evaluated as potential drug delivery systems for various administration routes. Targeting the drugs to certain physiological sites such as the lymph nodes has emerged as a promising strategy in treating TB with improved drug bioavailability and reduction of the dosing frequency. Nanotechnology based rational targeting may improve therapeutic success by limiting adverse drug effects and requiring less frequent administration regimes, ultimately resulting in more patients compliance and thus attain higher adherence levels. The development of nanoparticle based aerosol vaccine is undergoing which could serve as new platform for immunization. Present article compiles the general physiological aspects of the infection along with new research uptades on nanocarriers used in prevention of tuberculosis. _______________________________________________________________________________________

show abstract

“…Discussion and analysis on the major and new approaches and strategies currently employed in an effort to minimize the burden of leishmaniasis diseases and the major advancement occur in this field globally is the concern of this article. that invade to intracellular parasites with least toxicity and higher efficacy [9].…”

Section: Introductionmentioning

confidence: 99%

Untitled

2017

AJBVP

View full text Add to dashboard Cite

Parasitic diseases: Liposomes and polymeric nanoparticles versus lipid nanoparticles☆

Cited by 248 publications

References 134 publications

Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity

Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity

Present status of nanoparticle research for treatment of Tuberculosis

Untitled

Contact Info

Product

Resources

About